Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2005 in Intermediate/High-risk NMIBC
NCT06108492Phase 1Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-2005 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Hengrui Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicities, Maximum Tolerated Dose and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
SHR-2005
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06108492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108492.